Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

NCT00096395 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

NIH

Sponsor class

Conditions

Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer

Interventions

DRUG: gemcitabine hydrochloride
DRUG: sorafenib tosylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)